Depression News and Research

Latest Depression News and Research

Intra-Cellular Therapies announces results of its ITI-007 antipsychotic drug Phase I study

Intra-Cellular Therapies, Inc. (ITI) announced at a recent conference on neuropsychiatric diseases the results from a recently completed Phase I clinical study demonstrating ITI-007, the Company's lead antipsychotic drug, interacts with important targets in the living human brain. These key targets are critical to drug action in many neuropsychiatric and related disorders.

21 Dec 2009

CIGNA suggests the 'To Do' list to stay healthy during this holiday season

‘Tis the season for celebrating with family and friends -- and searching for those perfect gifts. CIGNA suggests adding another item to the top of the holiday “To Do” list: Be sure to take needed medications to stay healthy this holiday season and into the New Year.

19 Dec 2009

GSK receives European CHMP positive opinion for Revolade

Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has received a positive opinion for Revolade® (eltrombopag/Promacta®) from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).

18 Dec 2009

A program to reduce depression and isolation among the elderly during holiday season

MyWay Village, the first senior-focused technology company to help seniors get online in an easy and social way by combining access to simplified technology with personal training and support, today announced that their Connected Living program is reducing depression and feelings of isolation especially during the holiday season within senior communities where the company's programs are being offered.

18 Dec 2009

Researchers identify risk factors for major depression in elderly patients

University of Rochester Medical Center researchers have pinpointed the prime factors identifying which elderly persons are at the highest risk for developing major depression.

18 Dec 2009

Four commonly used chemotherapy drugs disrupt birth of new brain cells, shows study

Researchers have developed a novel animal model showing that four commonly used chemotherapy drugs disrupt the birth of new brain cells, and that the condition could be partially reversed with the growth factor IGF-1.

18 Dec 2009

Cannabis can cause depression and anxiety in teenagers

Canadian teenagers are among the largest consumers of cannabis worldwide. The damaging effects of this illicit drug on young brains are worse than originally thought, according to new research by Dr. Gabriella Gobbi, a psychiatric researcher from the Research Institute of the McGill University Health Centre. The new study, published in Neurobiology of Disease, suggests that daily consumption of cannabis in teens can cause depression and anxiety, and have an irreversible long-term effect on the brain.

18 Dec 2009

Somaxon Pharmaceuticals to meet FDA to discuss the NDA for Silenor for insomnia treatment

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today stated that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on January 20, 2010 to discuss the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia.

18 Dec 2009

Neurocrine Biosciences to sell 4,784,689 shares of common stock to Venrock affiliates

Neurocrine Biosciences, Inc. today reported that it has entered into a privately negotiated transaction to sell an aggregate of 4,784,689 primary shares of its common stock to affiliates of Venrock at a price of $2.09 per share, raising aggregate gross proceeds to Neurocrine of approximately $10 million. Neurocrine expects the financing to close on or about December 22, 2009, subject to customary closing conditions.

17 Dec 2009

Tips for healthy living for the year ahead

Whether you are a vegetarian, vegan, carnivore or pescetarian, vegetables should be a central part of your diet. Often referred to as a "protective food," dark green foods provide essential vitamins and nutrients to your body that protect you from many of life's worst diseases.

17 Dec 2009

ASA offers practical ways for sufferers to take active role in treatment of pain

Whether the result of injury, illness or a chronic condition, 70 million Americans experience pain annually. The individual pain sufferer may experience a diminished quality of life, lack of mobility and added stress.

17 Dec 2009

ARNMD meeting examines psychological and neurological aspects of PTSDs and traumatic brain injuries

War is hell, as the old saying goes -- with loss of life and limb, destruction of infrastructure and the environment, and devastating costs. Recent biomedical research has shed light on another pernicious consequence of military conflict: psychological and neurological conditions like post-traumatic stress disorder and traumatic brain injury. At the same time, researchers have worked to uncover some of the motives and meanings of war.

17 Dec 2009

HFU increases mortality among diabetics, says report

Cardium Therapeutics today reported on recent clinical findings published in the December issue of Diabetes Care showing an increase in mortality in diabetic patients with a history of foot ulcer (HFU) compared with diabetic patients without HFU and with non-diabetic patients.

17 Dec 2009

HHS Secretary Kathleen Sebelius announces $27 million to help older individuals with chronic conditions

HHS Secretary Kathleen Sebelius has announced the availability of $27 million to help older individuals with chronic conditions to improve their health and reduce their use of costly medical care.

17 Dec 2009

Naurex' GLYX-13 demonstrates antidepressant-like and anxiolytic-like activity without CNS-related side effects

Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that data presented at a major medical meeting showed that its lead compound GLYX-13 demonstrated robust antidepressant-like and anxiolytic-like activity with no signs of the CNS-related side effects seen with other drugs targeting the NMDA receptor.

16 Dec 2009

Naurex commences dosing in its GLYX-13 Phase I clinical trial for treatment-resistant depression

Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that it has initiated a Phase I clinical trial of its lead compound GLYX-13 and has successfully dosed the first subjects in the study.

16 Dec 2009

Positive results from Auxilium Pharmaceuticals' XIAFLEX Peyronie's disease phase IIb trial

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced top-line efficacy and safety results for the phase IIb clinical trial for XIAFLEX™ (collagenase clostridium histolyticum) in the treatment of Peyronie's disease.

16 Dec 2009

HealthInsight and HealthMedia join to deliver Internet-based Digital Coaching solutions

HealthInsight, provider of the only value-based health care administration platform, today announced a partnership with HealthMedia, Inc., a Johnson & Johnson company, to deliver Internet-based Digital Coaching™ solutions focused on lifestyle and behavioral change.

16 Dec 2009

Study suggests physical activity influences depression and fatigue by increasing self-efficacy

Physical activity is known to reduce depression and fatigue in people struggling with chronic illness. A new study indicates that this effect stems from an individual's sense of mastery over - or belief in his or her ability to achieve - certain physical goals.

16 Dec 2009

Binghamton University psychologist to provide new weapons to fight against childhood depression

Research by Binghamton University psychologist Brandon Gibb could provide new weapons for the fight against childhood depression. Working with colleagues around the country, he hopes to identify the causes of mental-health problems in kids and define trajectories of risk for depression.

16 Dec 2009

Depression News and Research

Latest Depression News and Research

Intra-Cellular Therapies announces results of its ITI-007 antipsychotic drug Phase I study

CIGNA suggests the 'To Do' list to stay healthy during this holiday season

GSK receives European CHMP positive opinion for Revolade

A program to reduce depression and isolation among the elderly during holiday season

Researchers identify risk factors for major depression in elderly patients

Four commonly used chemotherapy drugs disrupt birth of new brain cells, shows study

Cannabis can cause depression and anxiety in teenagers

Somaxon Pharmaceuticals to meet FDA to discuss the NDA for Silenor for insomnia treatment

Neurocrine Biosciences to sell 4,784,689 shares of common stock to Venrock affiliates

Tips for healthy living for the year ahead

ASA offers practical ways for sufferers to take active role in treatment of pain

ARNMD meeting examines psychological and neurological aspects of PTSDs and traumatic brain injuries

HFU increases mortality among diabetics, says report

HHS Secretary Kathleen Sebelius announces $27 million to help older individuals with chronic conditions

Naurex' GLYX-13 demonstrates antidepressant-like and anxiolytic-like activity without CNS-related side effects

Naurex commences dosing in its GLYX-13 Phase I clinical trial for treatment-resistant depression

Positive results from Auxilium Pharmaceuticals' XIAFLEX Peyronie's disease phase IIb trial

HealthInsight and HealthMedia join to deliver Internet-based Digital Coaching solutions

Study suggests physical activity influences depression and fatigue by increasing self-efficacy

Binghamton University psychologist to provide new weapons to fight against childhood depression

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Depression News and Research

Latest Depression News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in